跳至主要内容
临床试验/JPRN-jRCTs052190087
JPRN-jRCTs052190087招募中未知

Repetitive transcranial magnetic stimulation of the precentral-gyrus in the relief of fibromyalgia pain: an international multicenter controlled adaptive trial - TMSFFI

Kishima Haruhiko0 个研究点目标入组 10 人开始时间: 2019年12月23日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 <= 80age old(—)
性别
Female

入选标准

  • (1) Female patients with diagnosis fibromyalgia according to the ACR 2016 criteria (patient satisfies modified 2016 fibromyalgia criteria if the following 3 conditions are met
  • i) widespread pain index (WPI) >= 7 and symptom severity scale (SSS) score >= 5 or WPI of 3-6 and SSS score >= 9.
  • ii) Generalized pain, defined as pain in at least 4 of 5 regions, must be present. Jaw, chest, and abdominal pain are not included in generalized pain definition.
  • iii) Symptoms have been generally present for at least 3 months.
  • (2) Persistent pain for more than 6 months before enrollment.
  • (3) Stable treatment for atleast 2 months before enrollment and throughout the study.
  • (4) Age of 20 to 80 years.
  • (5) Right-handed patients.
  • (6) Be able to understand study protocol and give signed, written informed consent.
  • (7) NRS score >= 4/10

排除标准

  • (1) Known abuse of alcohol or illicit drugs
  • (2) Known psychiatric conditions (DSM-V)
  • (3) Contraindications to rTMS (Head trauma or concussion, metal implants in the skull, cardiac pacemaker, medication infusion devices, previous troubles with TMS or MRI)
  • (4) Pregnancy or breastfeeding
  • Being under chronic contraceptive use (intrauterine dispositive or oral contraceptive)
  • (5) Other medical conditions demand hospitalization;
  • (6) Participation in other clinical studies at the same time
  • (7) Use of strong opioids
  • (8) Transcranial magnetic stimulation-naive
  • (9) Inflammatory rheumatic disease, autoimmune disease, or other painful disorders that might confound the assessment of fibromyalgia pain
  • (10) On medications known to increase the risk of TMS-induced seizures (eg, theophylline, Ritalin, high-dose thyroid supplementation)
  • (11) If they had medication changes within 4 weeks of starting the trial or during the trial
  • (12) Neurologic disorders
  • (13) If they had stroke, bipolar disorder, or schizophrenia

研究者

发起方
Kishima Haruhiko

相似试验